Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Gains from Sales and Divestitures (2018 - 2020)

Historic Gains from Sales and Divestitures for United Therapeutics (UTHR) over the last 3 years, with Q1 2020 value amounting to $104818.0.

  • United Therapeutics' Gains from Sales and Divestitures rose 12773.15% to $104818.0 in Q1 2020 from the same period last year, while for Mar 2020 it was $104818.0, marking a year-over-year increase of 12773.15%. This contributed to the annual value of $74324.0 for FY2019, which is 29013.18% up from last year.
  • As of Q1 2020, United Therapeutics' Gains from Sales and Divestitures stood at $104818.0, which was up 12773.15% from $74324.0 recorded in Q4 2019.
  • In the past 5 years, United Therapeutics' Gains from Sales and Divestitures ranged from a high of $104818.0 in Q1 2020 and a low of $17820.0 during Q2 2018
  • Its 3-year average for Gains from Sales and Divestitures is $51762.5, with a median of $55192.0 in 2019.
  • Per our database at Business Quant, United Therapeutics' Gains from Sales and Divestitures surged by 29013.18% in 2019 and then surged by 12773.15% in 2020.
  • Quarter analysis of 3 years shows United Therapeutics' Gains from Sales and Divestitures stood at $19051.0 in 2018, then soared by 290.13% to $74324.0 in 2019, then soared by 41.03% to $104818.0 in 2020.
  • Its Gains from Sales and Divestitures stands at $104818.0 for Q1 2020, versus $74324.0 for Q4 2019 and $69761.0 for Q3 2019.